Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma

Extravasation can present serious accidental complication of intravenous drug application. While monoclonal antibodies do not show the necrotic potential of cytotoxic chemotherapy drugs, considerable inflammatory toxicity can occur, necessitating standardized operating procedures for the management...

Full description

Bibliographic Details
Main Authors:	Michael Launspach, Marita Seif, Theresa M. Thole, Patrick Jesse, Joachim Schulz, Johannes H. Schulte, Susan Bischoff, Angelika Eggert, Hedwig E. Deubzer
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	Children
Subjects:	cancer immunotherapy monoclonal antibody soft tissue inflammation
Online Access:	https://www.mdpi.com/2227-9067/8/2/91

Similar Items

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
by: Keyel ME, et al.
Published: (2018-12-01)

Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01)

Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
by: Neofit Spasov, et al.
Published: (2021-01-01)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
by: Tim Flaadt, et al.
Published: (2023-09-01)

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
by: Felix Zirngibl, et al.
Published: (2020-10-01)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
by: Jasminka Stepan Giljević, et al.
Published: (2022-06-01)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
by: Aleksandra Wieczorek, et al.
Published: (2022-04-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
by: Nur Olgun, et al.
Published: (2022-12-01)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
by: Filiz Cicek, et al.
Published: (2020-12-01)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
by: Ruth Ladenstein, et al.
Published: (2020-01-01)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
by: Margaret Cupit-Link, et al.
Published: (2023-09-01)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
by: Aleksandra Wieczorek, et al.
Published: (2023-08-01)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2023-06-01)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
by: Holger N. Lode, et al.
Published: (2023-06-01)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
by: Stefano Mastrangelo, et al.
Published: (2021-11-01)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD<sub>2</sub> Antibody Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2022-10-01)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
by: Sascha Troschke-Meurer, et al.
Published: (2023-01-01)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
by: Kimberly J. Ornell, et al.
Published: (2020-04-01)

Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry
by: Danny Jazmati, et al.
Published: (2022-10-01)

Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing
by: Annabell Szymansky, et al.
Published: (2021-07-01)

Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics
by: Marco Lodrini, et al.
Published: (2022-04-01)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
by: Paula Martínez-Sanz, et al.
Published: (2021-08-01)

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
by: Michelle E. Keyel, et al.
Published: (2023-09-01)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
by: Sara Marie Ivasko, et al.
Published: (2023-01-01)

Immune response to racotumomab in a child with relapsed neuroblastoma
by: CLAUDIA VANESA SAMPOR, et al.
Published: (2012-12-01)

Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy
by: Solin Ali, et al.
Published: (2020-03-01)

A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization
by: Laura Grunewald, et al.
Published: (2021-06-01)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
by: Victor M. Villalobos, et al.
Published: (2020-02-01)

Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging
by: Zhiyang Wu, et al.
Published: (2021-06-01)

Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform
by: Dongwei Wu, et al.
Published: (2021-12-01)

Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect
by: Birte Arlt, et al.
Published: (2021-01-01)

Photostimulation of Extravasation of Beta-Amyloid through the Model of Blood-Brain Barrier
by: Ekaterina Zinchenko, et al.
Published: (2020-06-01)

On fuzzy soft $ \beta $-continuity and $ \beta $-irresoluteness: some new results
by: Ibtesam Alshammari, et al.
Published: (2024-03-01)

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain
by: Xin‐Yuan Liu, et al.
Published: (2022-09-01)

Large-scale production of monoclonal antibodies in suspension culture /
by: 271860 Backer, M. P., et al.

Dilemmas in the Management of an Infant with Neuroblastoma Metastasized to the Muscles
by: Jaques van Heerden, et al.
Published: (2023-07-01)

Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine
by: Lucrezia Galassi, et al.
Published: (2023-02-01)

Novel Treatments and Technologies Applied to the Cure of Neuroblastoma
by: Irene Paraboschi, et al.
Published: (2021-06-01)